Cargando…

Oncolytic Virotherapy for Hematological Malignancies

Hematological malignancies such as leukemias, lymphomas, multiple myeloma (MM), and the myelodysplastic syndromes (MDSs) primarily affect adults and are difficult to treat. For high-risk disease, hematopoietic stem cell transplant (HCT) can be used. However, in the setting of autologous HCT, relapse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bais, Swarna, Bartee, Eric, Rahman, Masmudur M., McFadden, Grant, Cogle, Christopher R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265224/ https://www.ncbi.nlm.nih.gov/pubmed/22312362 http://dx.doi.org/10.1155/2012/186512

Ejemplares similares

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells
por: Bartee, Eric, et al.
Publicado: (2012)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021)

The use of oncolytic virotherapy in the neoadjuvant setting
por: Thomas, Raquela J, et al.
Publicado: (2022)

Syncytia Formation in Oncolytic Virotherapy
por: Burton, Chase, et al.
Publicado: (2019)

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
por: Lilly, Cameron L., et al.
Publicado: (2016)

Tumor Tropism of DNA Viruses for Oncolytic Virotherapy
por: Enow, Junior A., et al.
Publicado: (2023)

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
por: Villa, Nancy Y., et al.
Publicado: (2016)

Cytokine determinants of viral tropism
por: McFadden, Grant, et al.
Publicado: (2009)

Oncolytic virotherapy for pediatric malignancies: future prospects
por: Waters, Alicia M, et al.
Publicado: (2016)

TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
por: Valenzuela-Cardenas, Miriam, et al.
Publicado: (2022)

Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy
por: Flores, Erica B., et al.
Publicado: (2020)

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
por: Phelps, Michael P., et al.
Publicado: (2018)

Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm
por: Guan, Mingxu, et al.
Publicado: (2014)

Oncolytic virotherapy for human malignant mesothelioma: recent advances
por: Boisgerault, Nicolas, et al.
Publicado: (2015)

ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)

Modulation of Tumor Necrosis Factor by Microbial Pathogens
por: Rahman, Masmudur M, et al.
Publicado: (2006)

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
por: Babiker, Hani M, et al.
Publicado: (2017)

Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020)

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy
por: Guan, Mingxu, et al.
Publicado: (2016)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

The Multifaceted Role of Macrophages in Oncolytic Virotherapy
por: Hofman, Laura, et al.
Publicado: (2021)

Editorial: Oncolytic virotherapy
por: Al-Shammari, Ahmed Majeed, et al.
Publicado: (2023)

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
por: Sampath, Padma, et al.
Publicado: (2015)

Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease
por: Villa, Nancy Y., et al.
Publicado: (2018)

Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies
por: Ekeke, Chigozirim N., et al.
Publicado: (2021)

Modulation of NF-κB signalling by microbial pathogens
por: Rahman, Masmudur M., et al.
Publicado: (2011)

Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Role of cytokines in poxvirus host tropism and adaptation
por: Rahman, Masmudur M, et al.
Publicado: (2022)

Oncolytic Virotherapy of Canine and Feline Cancer
por: Gentschev, Ivaylo, et al.
Publicado: (2014)

Oncolytic virotherapy for advanced liver tumours
por: Chang, Ju-Fang, et al.
Publicado: (2009)

Oncolytic Virotherapy for Cancer: Clinical Experience
por: Chaurasiya, Shyambabu, et al.
Publicado: (2021)

Oncolytic Virotherapy: The Cancer Cell Side
por: Ehrlich, Marcelo, et al.
Publicado: (2021)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021)

Measles virus: Background and oncolytic virotherapy
por: Bhattacharjee, Sankhajit, et al.
Publicado: (2018)

Multidisciplinary oncolytic virotherapy for gastrointestinal cancer
por: Fujiwara, Toshiyoshi
Publicado: (2019)

Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_se432bbu1u0aga6tednkmd7cag